BDRX — Biodexa Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $2.38m
- -$4.74m
- £0.38m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.674 | 0.343 | 0.578 | 0.699 | 0.381 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12 | 23.4 | 7.58 | 9.63 | 8.39 |
Operating Profit | -11.3 | -23 | -7 | -8.93 | -8.01 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.9 | -23.5 | -6.11 | -8.49 | -7.49 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.14 | -22.2 | -5.46 | -7.66 | -7.08 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -10.1 | -22.2 | -5.46 | -7.66 | -7.08 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.1 | -22.2 | -5.46 | -7.66 | -7.08 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -798 | -523 | -108 | -1.55 | -0.022 |